Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia.
Stem cell transplantation may lead to prolonged disease-free survival in young patients with high-risk myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia. About one-third of patients transplanted with an HLA-identical family donor will experience long-term disease-free survival. Outcome appears to be better for younger patients, patients with less advanced stages of MDS and treatment early in the course of the disease. The results of transplantation using partially matched family donors and phenotypically matched voluntary unrelated donors are still unsatisfactory, mainly due to significantly higher transplantation related mortality rate. For patients lacking a suitable sibling donor autologous stem cell transplantation may constitute an alternative. The presence of sufficient residual polyclonal stem cells and achieving a complete remission after chemotherapy forms a prerequisite for a successful transplantation. Further development of accurate prognostic classification systems will allow a risk-adapted strategy for an individual patient.